Biotechnology · Waltham, Massachusetts, United States
$21.82
+0.37% (+$0.08)2026-08-25
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Net Income-$55.8M
EPS$-1.33
Market Cap$1.4B
Price Performance
Historical data including institutional events
Company Profile
T
Tom Frohlich
CEO & Executive Director
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
The compnay also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
